Granules India is that pharma player who always shows up with paracetamol when you’ve got a hangover, but lately, it’s been giving investors their own headaches. Q1 FY26 clocked ₹1,210 Cr revenue (+3% YoY) and PAT of ₹132 Cr (-2% YoY). The company is juggling ransomware recovery, US FDA inspections, and a capex binge, all while trying to convince investors it’s more than just “paracetamol India Pvt Ltd.”
2. Introduction
Granules India, founded in Hyderabad, is a 40+ year veteran in APIs, PFIs, and Finished Dosages. Once dismissed as “just another bulk paracetamol supplier,” it has reinvented itself as a formulations-heavy player—64% of revenues now come from finished dosages, compared to 52% two years ago. That’s like going from “background character” to “lead role” in a pharma daily soap.
But the script isn’t always smooth. In FY24, an IT security incident (a.k.a. ransomware ka chamatkar) delayed product launches. Add to that an FDA warning letter for its Gagillapur plant, resignations of top executives, and investors started wondering if the company was running a pharma business or auditioning for a crime thriller.
Still, Granules ships products to 80+ countries, has a stronghold in CNS/ADHD drugs in the US, and is now moving into oncology and peptides. With ₹600 Cr capex lined up for Genome Valley expansion, the company is betting big on the future. The question: will it pay off before investors lose patience?
3. Business Model – WTF Do They Even Do?
Granules’ model is simple but layered, like a masala dosa:
APIs (22%) – The raw chemical blocks. Their paracetamol, metformin, and guaifenesin keep half the planet alive and sneezing in peace.
PFIs (14%) – The “ready-to-cook” mix. Pharma clients just transfer it from drum to hopper and voilà, medicine!
Finished Dosages (64%) – Tablets, capsules, bilayered, extended-release, rapid-release—basically all forms of “goli khol, goli khaa.”
Shift in focus: From low-margin APIs to higher-value finished dosages. Like moving from selling wheat to baking branded bread.
4. Financials Overview
Metric
Latest Qtr (Q1 FY26)
YoY (Q1 FY25)
Prev Qtr (Q4 FY25)
YoY %
QoQ %
Revenue
1,210 Cr
1,180 Cr
1,197 Cr
+2.6%
+1.1%
EBITDA
247 Cr
259 Cr
252 Cr
-4.6%
-2.0%
PAT
132 Cr
135 Cr
152 Cr
-2.2%
-13.2%
EPS (₹)
4.6
5.6
6.3
-17.9%
-27.0%
Commentary: Sales steady but margins slipping. EPS shrinkage makes the stock P/E (27x) look stretched compared to Dr Reddy’s (19x) or Cipla (23x).
5. Valuation Discussion – Fair Value Range
P/E Method: EPS ~₹20, industry median P/E ~30. Fair range: ₹450–₹600. CMP ₹528 is mid-zone.
EV/EBITDA Method: EV ~₹13,671 Cr, EBITDA ~₹950 Cr → ~14.4x, close to peer average.
DCF: With 10–12% revenue CAGR and margin recovery assumptions, DCF throws up ₹500–₹650.
Fair Value Range (Educational Purpose Only): ₹450–₹650. (Disclaimer: Educational purpose only, not investment advice.)
6. What’s Cooking – News, Triggers, Drama
FDA Inspection (Drama Special): Gagillapur unit under FDA scanner, warning letter still a hangover. Resolved partly, but investors remain jumpy.
Capex Binge: ₹600 Cr for Genome Valley (Hyderabad) finished dosage plant. 2.5 bn units ready by FY25-end. Target: 8 bn dosages capacity by 2026.
Acquisition Masala: Bought Switzerland’s Senn Chemicals AG for peptide/CDMO play. First serious step into complex molecules.
Leadership Turnover: CEO and senior execs resigned in 2025. Cue investor nervousness.
Product Pipeline: 16–18 launches in FY25; focus on oncology, anti-diabetic, nasal sprays.
